Amgen Inc. AMGN
Set alert
At close
Pre-market · Nov 2, 4:18 AM ET
- YTD
- +42.38%
- 1 year
- +59.59%
- Open
- 470.00
- Prev close
- 460.73
- Mkt cap
- 251.94B
- Vol
- 3.29M
- Avg vol
- 2.80M
- EPS
- 16.10
- P/E
- 28.94
- Div yield
- 2.19%
More statistics
- Low
- 465.33
- High
- 475.65
- Forward P/E
- 19.03
- Beta
- 0.41
- Short ratio
- 4.35
- Inst. own
- 85.07%
- Dividend
- 10.08
- Ex-div date
- Nov 19, 2026
- Earnings
- Nov 3, 2026
- 50-d avg
- 419.32
- 200-d avg
- 374.10
- 1y target
- 397.32
5D chart
Signals (119)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:25 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| RSI: Oversold | Oct 26, 11:40 AM | 6 days ago |
| RSI: Oversold | Oct 26, 11:05 AM | 6 days ago |
| RSI: Oversold | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
News
2 days ago 247wallst.com
How to Build $6,800 a Month in Dividend Income Without Selling a Single Share
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure…
3 days ago zacks.com
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close.
3 days ago zacks.com
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter…
3 days ago benzinga.com
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer
Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
3 days ago 247wallst.com
Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned…
4 days ago prnewswire.com
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of…
4 days ago zacks.com
Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?
Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
5 days ago prnewswire.com
AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the fourth quarter of 2026. The
5 days ago prnewswire.com
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New…
5 days ago fool.com
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight…
5 days ago zacks.com
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago fool.com
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net…
5 days ago seekingalpha.com
Amgen: A Biotech Bargain Heading Into Q3 Earnings
On November 3, Amgen Inc. will report its results for Q3. As a reminder, its Q2 non-GAAP EPS rose 25.8% quarter-on-quarter to $6.29, primarily due to the strong performance of biosimilars, Blincyto,…
6 days ago seekingalpha.com
TCW Concentrated Large Cap Growth Fund Q3 2026 Winners, Laggards, Buys & Sells
CRWD's NNARR of $333m grew 50.5% YoY. NOW's subscription revenue of $3.9b increased 24.5% YoY. In South Korean equity markets, AI-related stocks were down significantly.
6 days ago prnewswire.com
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS
THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.
6 days ago benzinga.com
Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer
Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.
6 days ago fool.com
Breakfast News: Science Strikes Back at Cancer
Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
6 days ago gurufocus.com
Is AMGN Overvalued? DCF Says Worth $204
On October 26, 2026, we conducted a DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance recently, with a year-to-date increase
-
1 week ago benzinga.com
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $480
Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $450 to $480.
-
1 week ago benzinga.com
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $400
Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $380 to $400.
1 week ago benzinga.com
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
-
1 week ago benzinga.com
Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and…
-
1 week ago benzinga.com
AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs.…
2 weeks ago benzinga.com
Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of…
2 weeks ago benzinga.com
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
-
2 weeks ago benzinga.com
Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.
-
2 weeks ago benzinga.com
BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415
BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Market Perform and lowers the price target from $450 to $415.
-
2 weeks ago benzinga.com
Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $430
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $435 to $430.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.
-
3 weeks ago benzinga.com
Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.
-
3 weeks ago benzinga.com
Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $440
Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $400 to $440.
-
3 weeks ago benzinga.com
Truist Securities Maintains Hold on Amgen, Raises Price Target to $380
Truist Securities analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $362 to $380.
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359
Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $362 to $359.
3 weeks ago benzinga.com
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
1 month ago benzinga.com
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
October 1, 2026 records indicate that Representative David Taylor filed a purchase of Amgen (NASDAQ:AMGN), valued between $3,003 and $45,000. According to the October filing, the transaction occurred…
-
finance.biggo.com
Wall Street's AI Trade Cracks: Nasdaq Sheds 2.86% as Alphabet, Intel Selloffs Expose Concentration Risk
The S&P 500 fell 0.9% in October even as 72% of its stocks rose, as a cap-weighted structure concentrated in AI names amplified losses from ...
-
ainvest.com
Icelandic DNA Trove Sparked Hunt for Next Ozempic
Amgen leverages Iceland's genetic database to develop MariTide, a dual-action obesity drug targeting GLP-1 and GIP pathways.
seekingalpha.com
SCHD Into Midterms: Healthcare A Concern
The Schwab US Dividend Equity ETF remains a Buy as dividend growth, diversification, and healthcare exposure shape the ...
tipranks.com
The Week That Was, The Week Ahead: Macro and Markets, November 1
U.S. stocks ended Friday sharply lower as disappointing technology earnings and concerns over massive AI spending sent Wall ...
seekingalpha.com
JEPI Vs. DIVO: The Right Income ETF For A Volatile 2027
The Amplify CWP Enhanced Dividend Income ETF is favored over JPMorgan Equity Premium Income ETF for 2026–2027. Check out the ...
finance.yahoo.com
Midterm Elections, Important Earnings and Other Key things to Watch this Week
Markets face a crowded week as midterm elections land Tuesday alongside a heavy earnings calendar. Apple (AAPL) and Palantir ...
-
theglobeandmail.com
Jobs Numbers Due Next Week
Algoma Central last week announced that, due to strong demand, it has entered into a revised agreement with a syndicate of underwriters led by CIBC Capital Markets to increase the size of the ...
stockstory.org
Amgen (AMGN) reports Q3: everything you need to know ahead of earnings
Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know.
msn.com
Dow Jones futures rise after market sell-off; how midterm elections may swing stocks
Techs led another stock market sell-off. It's a time to be defensive. Apple, Palantir, jobs and midterm elections loom.
msn.com
Stocktwits Pharma Pulse: Biotech beats the broader market — Novo, Pfizer and Moderna earnings up next
Vertex will report results on Monday, putting Journavx and Casgevy sales and its $10 billion Crinetics acquisition in focus. ...